Drug Patent Watch

NOVEMBER 11, 2024

Effective management of drug patent portfolios is crucial for pharmaceutical companies to maintain market exclusivity, protect revenue streams, and drive innovation. A robust patent strategy aligned with business goals is essential for maximizing value and staying competitive in the pharmaceutical landscape.

Pharmaceutical Companies 105

Pharmaceutical Companies Drugs Pharmaceuticals Marketing 105

Drug Patent Watch

DECEMBER 8, 2024

The pharmaceutical industry is heavily reliant on patents to protect intellectual property and maintain market exclusivity. However, with the increasing competition from generic and biosimilar manufacturers, patent invalidity claims have become a significant challenge for pharmaceutical companies.

Biosimilars 98

Biosimilars Pharmaceutical Companies Drugs Pharmaceuticals 98

Drug Patent Watch

DECEMBER 30, 2024

This article aims to provide a comprehensive overview of the key aspects of the regulatory framework, highlighting the requirements and challenges faced by pharmaceutical companies seeking to introduce generic drugs into the Japanese market. New Drug Application (NDA) : Needed for marketing approval of new drugs.

Drug Development 52

Drug Development Clinical Pharmacology Clinical Trials Pharmaceutical Companies 52

Drug Patent Watch

FEBRUARY 13, 2025

The Unsung Heroes of Generic Drug Development: The Power of Partnerships As we navigate the complex landscape of pharmaceuticals, it's easy to overlook the crucial role that partnerships play in bringing affordable, life-saving medications to market. When it comes to developing generic drugs, partnerships can take many forms.

Drug Development 83

Drug Development Drugs Pharmaceutical Companies Treatment 83

PPD

NOVEMBER 11, 2024

As a result, biopharma and biotech companies working to bring their drug pipelines to the market require deep expertise from trusted partners to help deliver critical therapies for their patients. billion in 2023 to 1.2 billion in 2035.

Drug Development 97

Drug Development Clinical Trials Drugs Small Molecule 97

Drug Patent Watch

DECEMBER 17, 2024

Contract Development and Manufacturing Organizations (CDMOs) are at the forefront of this shift, playing a crucial role in bringing innovative therapies to market. Let’s dive into the world of pharmaceutical outsourcing and explore why adaptability is the key to success.

Pharmaceuticals 90

Pharmaceuticals Therapies Production Pharmaceutical Companies 90

Fierce BioTech

APRIL 4, 2025

The integration of AI-powered market intelligence offers pharmaceutical companies a competitive edge by enabling real-time insights, predictive analytics, and strategic decision-making. Join us to gain valuable insights into how pharmaceutical companies can leverage AI to achieve more with less.

Marketing 52

Marketing Pharmaceutical Companies Pharmaceuticals 52

Drug Target Review

DECEMBER 20, 2024

These innovations have started to shift industry perceptions, positioning AI as a transformative tool that could alter how drugs are developed, tested, and brought to market. Looking ahead, 2025 could represent a major turning point for the pharmaceutical sector.

Clinical Trials 128

Clinical Trials Trials Pharmaceuticals Drug Development 128

Drug Patent Watch

AUGUST 24, 2021

This chart shows the companies which have received the most GAIN Act exclusivities in the past five years. The Generating Antibiotic Incentives Now Act provides for five years of market…. The post Pharmaceutical companies with the most ‘Antibiotic GAIN Act’ drugs appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs Marketing 52

Drug Patent Watch

JUNE 27, 2024

Introduction Patent portfolios are critical assets for pharmaceutical companies, providing market exclusivity and protecting revenue streams for drug products. Effective management of drug patent portfolios requires strategic planning, ongoing evaluation, and adaptation to the evolving pharmaceutical landscape.

Pharmaceutical Companies 105

Pharmaceutical Companies Drugs Pharmaceuticals Production 105

Drug Patent Watch

JUNE 18, 2024

Branded generics are generic drugs that are marketed under a brand name by the manufacturer. Branded generics can be an attractive option for both consumers and pharmaceutical companies, offering cost savings while leveraging brand recognition. […] Source

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceuticals Production Marketing 105

Cytel

OCTOBER 11, 2023

Moving beyond static evidence development to ensure local market access success; responding to recent changes in governmental drug regulations and the role of automation Written by Grammati Sarri and Radek Wasiak The worldwide drug regulation landscape is rapidly changing.

Marketing 59

Marketing Pharmaceutical Companies Regulations Pharmaceuticals 59

DrugBank

AUGUST 9, 2024

Investment Trends in Pharmaceutical Research and Development Investing in the pharmaceutical sector presents a unique set of challenges and opportunities; let’s examine them in more detail.    The average cost of bringing a new drug to market is about $2.6 reported in 2021. trillion by 2028. million new cases.

Pharmaceuticals 98

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 98

Drug Discovery Today

JUNE 11, 2020

As the industry continues to see significant growth for drug products developed in prefilled syringe systems (PFS), there is a trend for pharmaceutical companies to evaluate more complex drug molecules, such as biologics.This webinar discusses current trends in the market for injectable drug delivery and outlines current challenges for companies developing (..)

Pharmaceutical Companies 113

Pharmaceutical Companies Pharmaceuticals Production Marketing 113

Drug Patent Watch

JANUARY 21, 2025

From identifying and prioritizing patent opportunities to leveraging data and analytics, we'll explore the strategies that top pharmaceutical companies are using to stay ahead of the curve. Identify and Prioritize Patent Opportunities With so many patent applications flooding the market, it's easy to get overwhelmed.

Drugs 59

Drugs Pharmaceutical Companies Pharmaceuticals Marketing 59

Drug Patent Watch

DECEMBER 9, 2024

From Lab to Market: The Long Road of Drug Development Once a promising compound is identified, it enters the long and costly process of drug development. This approach has led to the discovery of numerous potential drug candidates.

Drugs 97

Drugs Drug Development Pharmaceuticals Production 97

Fierce BioTech

AUGUST 7, 2024

The Unfiltered Truth about AI & Pharma Marketing dwunderlin Wed, 08/07/2024 - 12:04 Wed, 09/04/2024 - 14:00 Resource Type Webinar Chris Cullmann Doug Barr Promotion Start Thu, 08/08/2024 - 15:00 Promotion End Sat, 02/08/2025 - 15:00 Duration 60 Minutes You need to know where artificial intelligence disrupts the pharmaceutical marketing norms.

Marketing 52

Marketing Pharmaceutical Companies Pharmaceuticals Production 52

DrugBank

NOVEMBER 4, 2024

  The erosion of existing antibiotic efficacy due to resistance presents a challenge — an urgent public health crisis and a potential market opportunity. This costly, high-risk development pipeline has high attrition rates and uncertain market returns.  

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Government DNA 98

Drug Target Review

AUGUST 6, 2024

How do companies prioritise their R&D investment between oncology and other therapeutic areas for ADCs? This prioritisation is based on a combination of market demand, scientific feasibility, regulatory environment, competitive landscape, potential for breakthrough therapies, strategic fit, partnerships, and financial considerations.

Therapies 119

Therapies Pharmaceutical Companies Disease Treatment 119

DrugBank

MARCH 7, 2024

The landscape of weight loss drugs has been rapidly evolving, and 2024 is poised to be another transformative year in this market. Pharmaceutical researchers, in particular, have a keen interest in understanding the unfolding dynamics of this market. Let’s delve into what lies ahead in the coming year.

Pharmaceutical Companies 98

Pharmaceutical Companies Clinical Trials Pharmaceuticals Therapies 98

Drug Patent Watch

AUGUST 24, 2022

This chart shows the companies which have received the most GAIN Act exclusivities in the past five years. The Generating Antibiotic Incentives Now Act provides for five years of market…. The post Pharmaceutical companies with the most ‘Antibiotic GAIN Act’ drugs appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceuticals Drugs Marketing 40

DrugBank

OCTOBER 4, 2024

Sophisticated valuation methodologies, such as the income, market, and cost approaches, are employed to estimate the fair value of individual patents or the entire IP portfolio. Emerging Markets Emerging markets, particularly in Asia and Latin America, have become increasingly attractive destinations for pharmaceutical M&A activity.

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

DrugBank

MARCH 15, 2024

According to Grand View Research , the global weight loss and weight management market size was valued at $142.5 Many drug discovery and repurposing initiatives are shifting focus to capturing a share of this market in light of Eli Lilly and the Novo Nordisk success. for this class of drugs.   billion and $41.6

Pharmaceutical Companies 97

Pharmaceutical Companies Pharmaceuticals Treatment Clinical Trials 97

thought leadership

SEPTEMBER 16, 2024

Our offshore contact centers in India and the Philippines offer pharmaceutical companies an unparalleled blend of innovation, customer excellence, and cost efficiency.

Pharmaceutical Companies 75

Pharmaceutical Companies Pharmaceuticals Marketing 75

The Pharma Data

APRIL 1, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it will host a conference call on April 6, 2021 to provide updates on select New Molecular Entities (NMEs) in its Wave 1 pipeline portfolio.

Marketing 52

Marketing Pharmaceutical Companies Production Treatment 52

Drug Patent Watch

DECEMBER 12, 2024

Ensure the CDMO has the resources to expand production as needed, avoiding bottlenecks that can slow time to market. This helps understand market dynamics and the ROI potential for CDMO investments. Conduct Due Diligence Perform enhanced due diligence to gain an objective view of the CDMO landscape and market size.

Drug Development 98

Drug Development Production Clinical Trials Pharmaceutical Companies 98

thought leadership

MAY 8, 2024

How ProPharma Can Help You Ensure Compliance with the New HTAR Requirements The new Health Technology Assessment Regulation (HTAR) will set new requirements for pharmaceutical companies seeking registration and market access in the European Union (EU) for their products.

Pharmaceutical Companies 59

Pharmaceutical Companies Compliance Pharmaceuticals Regulations 59

DrugBank

APRIL 12, 2024

Recently, the shift from an early-adopters market to an expansive early majority market in AI is undeniable, marking a universal shift among leaders in pharmaceuticals toward harnessing these technologies.  Stay tuned for part two coming soon. 

Drugs 98

Drugs Clinical Trials Pharmaceutical Companies Pharmaceuticals 98

The Pharma Data

JANUARY 24, 2021

million through the issuance of an aggregate 15,455,960 shares of its common stock and warrants to purchase up to an aggregate of 7,727,980 shares of common stock, at a purchase price of $1.294 per share of common stock and associated warrant in a private placement priced at-the-market under Nasdaq rules. CRANFORD, N.J. ,

Marketing 40

Marketing Pharmaceuticals Pharmaceutical Companies Production 40

Conversations in Drug Development Trends

DECEMBER 7, 2023

While large CROs will continue to play an important role in the clinical development space, now more than ever, there is a need for companies that place value on personalized collaboration.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

Common Sense for Drug Policy Blog

FEBRUARY 14, 2024

Entry and Availability of Nitazenes in the Unregulated Drug Market "During the 1950s, nitazenes were developed by commercial pharmaceutical companies as synthetic opioid candidates and they were described in medical and pharmaceutical literature of the era.

Marketing 40

Marketing Drugs Pharmaceutical Companies Pharmaceuticals 40

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

PPD

MARCH 26, 2024

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

Clinical Research 98

Clinical Research Pharmaceutical Companies Clinical Development Drug Development 98

DrugBank

AUGUST 15, 2024

To effectively navigate this ecosystem and expedite the development of new therapies, collaboration between the pharmaceutical industry and academia is proving increasingly vital. This includes funding large-scale clinical trials and establishing robust manufacturing/distribution networks.

Drug Development 98

Drug Development Clinical Trials Drugs Therapies 98

thought leadership

MAY 7, 2024

Pharmaceutical companies need to be prepared for the new European Health Technology Assessment Regulation (HTAR), which will take effect in January 2025. It is crucial for companies to establish new internal timelines and processes to bring drugs, and eventually also medical devices, to the European market.

Pharmaceutical Companies 59

Pharmaceutical Companies International Regulations Pharmaceuticals 59

Drug Target Review

SEPTEMBER 5, 2024

This was very challenging for me and at that moment I decided to get experience from later stage products and therefore took on the role as Global Product Director for late-stage marketed cardiovascular products. She is a Board director of GU Ventures, the holding company at the University of Gothenburg.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

DS in Pharmatics

FEBRUARY 24, 2023

Specialist regulatory affairs consultants offer services to companies operating across this challenging industry. Pharmaceutical companies and the drugs they develop must meet stringent regulations before products are approved for the market. Continue reading to learn how regulatory […]

Pharmaceutical Companies 52

Pharmaceutical Companies Regulations Drug Development Pharmaceuticals 52